ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
60,797.69
-0.15%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lixte Biotechnology Holdings Inc (LIXTW)

  7. Lixte Biotechnology Holdings Inc (LIXTW) News

Lixte Biotechnology (LIXTW)

Lixte Biotechnology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIXTW
DateTimeSourceHeadlineSymbolCompany
14/06/202419:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202416:00GlobeNewswire Inc.LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202414:30GlobeNewswire Inc.LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
14/06/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
06/06/202413:30GlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTWLixte Biotechnology Holdings Inc
05/06/202420:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
03/06/202413:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
29/05/202422:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202417:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/05/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTWLixte Biotechnology Holdings Inc
08/05/202414:25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTWLixte Biotechnology Holdings Inc
24/04/202420:25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202419:35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/03/202412:30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTWLixte Biotechnology Holdings Inc
21/03/202412:30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
27/02/202413:30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/02/202413:30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTWLixte Biotechnology Holdings Inc
29/01/202413:30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTWLixte Biotechnology Holdings Inc
13/11/202313:30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTWLixte Biotechnology Holdings Inc
16/10/202313:30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTWLixte Biotechnology Holdings Inc
09/10/202313:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTWLixte Biotechnology Holdings Inc
26/09/202313:30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/09/202313:30GlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTWLixte Biotechnology Holdings Inc
20/07/202321:05GlobeNewswire Inc.LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
18/07/202313:00GlobeNewswire Inc.LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq RulesNASDAQ:LIXTWLixte Biotechnology Holdings Inc
17/07/202313:30GlobeNewswire Inc.Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and ChemotherapyNASDAQ:LIXTWLixte Biotechnology Holdings Inc
01/12/202017:30GlobeNewswire Inc.Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to NasdaqNASDAQ:LIXTWLixte Biotechnology Holdings Inc
30/11/202020:52Business WireWestPark Capital Announces Closing of $5,700,000 Follow-On Offering & NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc....NASDAQ:LIXTWLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXTW

Your Recent History

USOTC
NHCZF
Nihon Chouzai (PK)
BIT
S29790
Societe Generale Effekten
AMEX
TOUS
T Rowe Price Internation...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved